Liwei Ren1, Yuan Sun1, Hong Lu1, Dien Ye1, Lijuan Han1, Na Wang1, Alan Daugherty1, Furong Li1, Miaomiao Wang1, Fengting Su1, Wenjun Tao1, Jie Sun1, Noam Zelcer1, Adam E Mullick1, A H Jan Danser1, Yizhou Jiang1, Yongcheng He1, Xiongzhong Ruan2, Xifeng Lu2. 1. From the AstraZeneca-Shenzhen University Joint Institute of Nephrology, Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, China (L.R., Y.S., D.Y., L.H., N.W., M.W., F.S., W.T., J.S., X.R., X.L.); Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China (L.R., Y.S., F.L., X.L.); Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam University, The Netherlands (L.R., Y.S., A.H.J.D.); Saha Cardiovascular Research Center and Department of Physiology, University of Kentucky, Lexington (H.L., A.D.); Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands (N.Z.); Ionis Pharmaceuticals, Inc, Carlsbad, CA (A.E.M.); Institute for Advanced Study, Shenzhen University, China (Y.J.); The First Affiliated Hospital of Shenzhen University, China (Y.H.); and John Moorhead Laboratory, Center for Nephrology, University College London, United Kingdom (X.R.). 2. From the AstraZeneca-Shenzhen University Joint Institute of Nephrology, Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, China (L.R., Y.S., D.Y., L.H., N.W., M.W., F.S., W.T., J.S., X.R., X.L.); Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China (L.R., Y.S., F.L., X.L.); Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam University, The Netherlands (L.R., Y.S., A.H.J.D.); Saha Cardiovascular Research Center and Department of Physiology, University of Kentucky, Lexington (H.L., A.D.); Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands (N.Z.); Ionis Pharmaceuticals, Inc, Carlsbad, CA (A.E.M.); Institute for Advanced Study, Shenzhen University, China (Y.J.); The First Affiliated Hospital of Shenzhen University, China (Y.H.); and John Moorhead Laboratory, Center for Nephrology, University College London, United Kingdom (X.R.). x.lu@szu.edu.cn xiongzruan@gmail.com.
Abstract
RATIONALE: An elevated level of plasma LDL (low-density lipoprotein) is an established risk factor for cardiovascular disease. Recently, we reported that the (pro)renin receptor ([P]RR) regulates LDL metabolism in vitro via the LDLR (LDL receptor) and SORT1 (sortilin-1), independently of the renin-angiotensin system. OBJECTIVES: To investigate the physiological role of (P)RR in lipid metabolism in vivo. METHODS AND RESULTS: We used N-acetylgalactosamine modified antisense oligonucleotides to specifically inhibit hepatic (P)RR expression in C57BL/6 mice and studied the consequences this has on lipid metabolism. In line with our earlier report, hepatic (P)RR silencing increased plasma LDL-C (LDL cholesterol). Unexpectedly, this also resulted in markedly reduced plasma triglycerides in a SORT1-independent manner in C57BL/6 mice fed a normal- or high-fat diet. In LDLR-deficient mice, hepatic (P)RR inhibition reduced both plasma cholesterol and triglycerides, in a diet-independent manner. Mechanistically, we found that (P)RR inhibition decreased protein abundance of ACC (acetyl-CoA carboxylase) and PDH (pyruvate dehydrogenase). This alteration reprograms hepatic metabolism, leading to reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)RR inhibition attenuated diet-induced obesity and hepatosteatosis. CONCLUSIONS: Collectively, our study suggests that (P)RR plays a key role in energy homeostasis and regulation of plasma lipids by integrating hepatic glucose and lipid metabolism.
RATIONALE: An elevated level of plasma LDL (low-density lipoprotein) is an established risk factor for cardiovascular disease. Recently, we reported that the (pro)renin receptor ([P]RR) regulates LDL metabolism in vitro via the LDLR (LDL receptor) and SORT1 (sortilin-1), independently of the renin-angiotensin system. OBJECTIVES: To investigate the physiological role of (P)RR in lipid metabolism in vivo. METHODS AND RESULTS: We used N-acetylgalactosamine modified antisense oligonucleotides to specifically inhibit hepatic (P)RR expression in C57BL/6 mice and studied the consequences this has on lipid metabolism. In line with our earlier report, hepatic (P)RR silencing increased plasma LDL-C (LDL cholesterol). Unexpectedly, this also resulted in markedly reduced plasma triglycerides in a SORT1-independent manner in C57BL/6 mice fed a normal- or high-fat diet. In LDLR-deficient mice, hepatic (P)RR inhibition reduced both plasma cholesterol and triglycerides, in a diet-independent manner. Mechanistically, we found that (P)RR inhibition decreased protein abundance of ACC (acetyl-CoA carboxylase) and PDH (pyruvate dehydrogenase). This alteration reprograms hepatic metabolism, leading to reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)RR inhibition attenuated diet-induced obesity and hepatosteatosis. CONCLUSIONS: Collectively, our study suggests that (P)RR plays a key role in energy homeostasis and regulation of plasma lipids by integrating hepatic glucose and lipid metabolism.
Authors: Ling Qi; Jose E Heredia; Judith Y Altarejos; Robert Screaton; Naomi Goebel; Sherry Niessen; Ian X Macleod; Chong Wee Liew; Rohit N Kulkarni; James Bain; Christopher Newgard; Michael Nelson; Ronald M Evans; John Yates; Marc Montminy Journal: Science Date: 2006-06-23 Impact factor: 47.728
Authors: Fabian Riediger; Ivo Quack; Fatimunnisa Qadri; Björn Hartleben; Joon-Keun Park; Sebastian A Potthoff; Dennis Sohn; Gabin Sihn; Anthony Rousselle; Verena Fokuhl; Ulrike Maschke; Bettina Purfürst; Wolfgang Schneider; Lars C Rump; Friedrich C Luft; Ralf Dechend; Michael Bader; Tobias B Huber; Genevieve Nguyen; Dominik N Muller Journal: J Am Soc Nephrol Date: 2011-10-27 Impact factor: 10.121
Authors: J Fan; S P McCormick; R M Krauss; S Taylor; R Quan; J M Taylor; S G Young Journal: Arterioscler Thromb Vasc Biol Date: 1995-11 Impact factor: 8.311
Authors: Oksana Gavrilova; Martin Haluzik; Kimihiko Matsusue; Jaime J Cutson; Lisa Johnson; Kelly R Dietz; Christopher J Nicol; Charles Vinson; Frank J Gonzalez; Marc L Reitman Journal: J Biol Chem Date: 2003-06-11 Impact factor: 5.157
Authors: Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser Journal: Pharmacol Rev Date: 2022-07 Impact factor: 18.923
Authors: Eva Gatineau; Gertrude Arthur; Audrey Poupeau; Kellea Nichols; Brett T Spear; Nathan R Shelman; Gregory A Graf; Ryan E Temel; Frédérique B Yiannikouris Journal: Am J Physiol Endocrinol Metab Date: 2021-01-18 Impact factor: 4.310
Authors: Tomasz Pizoń; Marek Rajzer; Wiktoria Wojciechowska; Małgorzata Wach-Pizoń; Tomasz Drożdż; Katarzyna Wróbel; Krystian Gruszka; Marta Rojek; Tomasz Kameczura; Artur Jurczyszyn; Janusz Kąkol; Danuta Czarnecka Journal: J Renin Angiotensin Aldosterone Syst Date: 2018 Oct-Dec Impact factor: 1.636
Authors: Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468
Authors: Na Wang; Lishu He; Hui Lin; Lunbo Tan; Yuan Sun; Xiaoying Zhang; A H Jan Danser; Hong S Lu; Yongcheng He; Xifeng Lu Journal: PLoS One Date: 2020-05-21 Impact factor: 3.240